Fortem Financial Group LLC Has $525,000 Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Fortem Financial Group LLC decreased its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 30.0% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 6,263 shares of the biopharmaceutical company’s stock after selling 2,689 shares during the period. Fortem Financial Group LLC’s holdings in Gilead Sciences were worth $525,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of GILD. TT International Asset Management LTD acquired a new stake in shares of Gilead Sciences in the third quarter valued at approximately $1,257,000. Coldstream Capital Management Inc. grew its position in Gilead Sciences by 9.8% in the third quarter. Coldstream Capital Management Inc. now owns 22,882 shares of the biopharmaceutical company’s stock valued at $1,932,000 after purchasing an additional 2,043 shares in the last quarter. Gould Capital LLC increased its stake in Gilead Sciences by 22.2% in the 3rd quarter. Gould Capital LLC now owns 16,128 shares of the biopharmaceutical company’s stock valued at $1,352,000 after buying an additional 2,927 shares during the last quarter. Geode Capital Management LLC lifted its position in Gilead Sciences by 2.1% during the 3rd quarter. Geode Capital Management LLC now owns 27,540,870 shares of the biopharmaceutical company’s stock worth $2,302,119,000 after buying an additional 574,421 shares in the last quarter. Finally, Brophy Wealth Management LLC acquired a new position in shares of Gilead Sciences during the 3rd quarter worth about $1,275,000. Institutional investors own 83.67% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the company. Barclays upped their target price on Gilead Sciences from $84.00 to $95.00 and gave the stock an “equal weight” rating in a report on Thursday, November 7th. Sanford C. Bernstein started coverage on shares of Gilead Sciences in a report on Thursday, October 17th. They set an “outperform” rating and a $105.00 target price on the stock. Robert W. Baird lifted their price objective on shares of Gilead Sciences from $80.00 to $95.00 and gave the company a “neutral” rating in a research report on Thursday, November 7th. Oppenheimer lifted their price target on Gilead Sciences from $105.00 to $115.00 and gave the stock an “outperform” rating in a report on Tuesday. Finally, Bank of America reissued a “buy” rating and set a $109.00 price target on shares of Gilead Sciences in a research report on Tuesday. Twelve research analysts have rated the stock with a hold rating, twelve have issued a buy rating and four have given a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $96.43.

Gilead Sciences Stock Up 1.9 %

Shares of NASDAQ GILD opened at $92.34 on Wednesday. The stock has a 50-day moving average price of $89.33 and a two-hundred day moving average price of $78.89. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $98.90. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. The company has a market cap of $115.08 billion, a price-to-earnings ratio of 1,026.00, a PEG ratio of 2.86 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, topping analysts’ consensus estimates of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The firm had revenue of $7.55 billion for the quarter, compared to analysts’ expectations of $7.01 billion. During the same quarter in the previous year, the firm posted $2.29 earnings per share. The company’s revenue was up 7.0% on a year-over-year basis. As a group, analysts forecast that Gilead Sciences, Inc. will post 4.37 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 30th. Investors of record on Friday, December 13th will be issued a $0.77 dividend. The ex-dividend date is Friday, December 13th. This represents a $3.08 dividend on an annualized basis and a yield of 3.34%. Gilead Sciences’s dividend payout ratio (DPR) is presently 3,422.22%.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total transaction of $167,660.00. Following the completion of the sale, the insider now directly owns 100,189 shares in the company, valued at approximately $8,398,843.87. This trade represents a 1.96 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Johanna Mercier sold 29,357 shares of the business’s stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $83.78, for a total value of $2,459,529.46. Following the completion of the transaction, the insider now directly owns 78,127 shares in the company, valued at $6,545,480.06. This represents a 27.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 476,591 shares of company stock worth $43,747,615. 0.29% of the stock is currently owned by company insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.